After being present in the Turkish market for more than 28 years, MSD seems confident that it will be able to seize upcoming opportunities due to the country’s high prevalence of chronic disease, strong national immunization program and increasing life expectancy. Its general manager for the Turkey cluster, Gözde Güllüoğlu, comments on the American company’s priorities after the Organon spinoff, their leadership position in clinical trials and why her rise within the organization reflects MSD’s commitment to diversity and inclusion.
It has become evident during the pandemic that Turkey has a well-established and capable healthcare system with experienced healthcare professionals (HCPs). Considering all these aspects, double-digit growth in the market is to be expected
